The first phase II "sound and light" therapy for Alzheimer's has positive results

Alzheimer's disease (AD) is a devastating neurodegenerative disease with unknown etiology, mostly in middle-aged and elderly people, affecting tens of millions of people worldwide.

On March 9, Cognito Therapeutics, a clinical stage company in the United States, announced at the 15th International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2021) that it has developed an innovative digital approach for the treatment of AD through sound and light stimulation.

Cognito Therapeutics' patented gamma frequency neuromodulation platform technology was developed by Professor Lihui Cai and Professor Ed Boyden of the Massachusetts Institute of Technology.

As early as 2016, Cai Lihui’s team first reported in Nature that the use of LED lights to emit flashes of special frequency can reduce amyloid deposits in the brains of mice that are prone to AD symptoms after genetic modification.

These studies have laid a good foundation for clinical trials.

The test results show that gamma frequency neuromodulation is safe and well tolerated.

Cognito CEO Brent Vaughan said: "Recently, the digital therapy we developed has been granted a breakthrough medical device designation by the U.

Reference materials:

1# Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer's Disease (Source: business wire)

2# Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture) (Source: ClinicalTrials.

4# In-depth report on Alzheimer's disease treatment: from amyloid and Tau protein drugs to stem cells and gene therapy (Source: Medical Rubik's Cube Pro)

5# Can Su Daqiang get a serious illness? Maybe you can save without taking medicine | Cell's disruptive breakthrough (Source: Medical Rubik's Cube Pro)